
Annual report 2023
added 12-27-2025
Biophytis SA EPS Ratio 2011-2026 | BPTS
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Biophytis SA
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -0.26 | -0.43 | -1.12 | -1.05 | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.26 | -1.12 | -0.715 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
-0.78 | $ 1.06 | -0.93 % | $ 5.78 M | ||
|
Adagene
ADAG
|
-0.59 | $ 1.65 | - | $ 92.9 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.45 | 3.6 % | $ 8.3 B | ||
|
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | ||
|
Biogen
BIIB
|
11.2 | $ 187.4 | 0.75 % | $ 27.3 B | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Legend Biotech Corporation
LEGN
|
-1.37 | $ 23.58 | 2.39 % | $ 18.7 B | ||
|
Ascendis Pharma A/S
ASND
|
-8.28 | $ 201.94 | -3.26 % | $ 5 B | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
BioNTech SE
BNTX
|
42.2 | $ 99.81 | 0.97 % | $ 27.2 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-0.09 | - | -15.15 % | $ 60.3 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-0.01 | $ 4.14 | -3.72 % | $ 9.01 B | ||
|
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
3.29 | $ 27.75 | 0.02 % | $ 1.34 B | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
75.3 | $ 9.44 | 1.78 % | $ 1.52 B | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
-10.1 | - | -6.81 % | $ 3.04 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-0.01 | $ 64.9 | -0.15 % | $ 8.68 B | ||
|
Athersys
ATHX
|
-0.39 | - | 3.77 % | $ 22.4 M | ||
|
Evogene Ltd.
EVGN
|
-0.83 | $ 1.1 | -0.45 % | $ 27.9 M | ||
|
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.82 | -4.85 % | $ 464 M | ||
|
Abeona Therapeutics
ABEO
|
-2.53 | $ 5.17 | 1.47 % | $ 111 M | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
Axon Enterprise
AXON
|
4.98 | $ 633.45 | 3.34 % | $ 48 B | ||
|
ADiTx Therapeutics
ADTX
|
-3.06 K | $ 0.8 | -4.43 % | $ 10.5 K | ||
|
Aytu BioScience
AYTU
|
-2.16 | $ 2.64 | -0.75 % | $ 16.6 M | ||
|
AstraZeneca PLC
AZN
|
0.08 | $ 94.65 | 0.68 % | $ 96.9 B | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M |